Amyloidosis

Amyloidosis in brief

Amyloidosis is an umbrella term for many different diseases that have in common that misfolded proteins are deposited in organs and tissues and disrupt their natural function there. These are rare diseases with different causes, different courses, and different treatments. In principle, anyone can develop amyloidosis; depending on the type, even children can be affected. An early diagnosis is crucial for treatment, because the disease is progressive and the aim is to prevent irreversible organ damage.

Amyloidosis at a glance

Type of disease
Umbrella term for many different diseases in which misfolded proteins are deposited in organs and tissues
Frequency
Rare diseases
Who can be affected?
In principle anyone; depending on the type, even children
Diagnosis
An early diagnosis is crucial for treatment

What exactly is amyloidosis?

The term "amyloid" was coined as early as the 19th century by the German physician Rudolf Virchow and describes accumulations of misfolded proteins. Because of misfolding, proteins cannot be broken down properly and accumulate in organs and tissues, which disrupts their function. The term amyloidoses covers various protein-folding diseases that differ in which protein is misfolded and are named accordingly. Common amyloidoses that affect the whole body (systemic amyloidoses) are:

  • AL amyloidosis (L = light chains, which are components of antibodies)
  • AA amyloidosis (A = serum amyloid A, a protein that is produced during infections or inflammation)
  • ATTR amyloidosis (TTR = transthyretin, a transport protein in the blood that carries thyroid hormones and vitamin A)

Why do I have amyloidosis?

There are various causes of amyloidosis; they can be either acquired or hereditary. Acquired here means that they arise, for example, from other underlying diseases or from the body's natural aging process.

  • AL amyloidosis: associated with plasma cell disorders (multiple myeloma, monoclonal gammopathy of undetermined significance, Waldenström's macroglobulinemia, and other B-cell lymphomas). These affect the cells of the immune system that normally produce antibodies to defend against pathogens (plasma cells). In these diseases, increased amounts of antibody fragments (light chains) are produced. If misfolding also occurs, these light chains are deposited in large quantities as amyloid in organs.
  • AA amyloidosis: can occur in chronic inflammatory or chronic infectious diseases, such as rheumatoid arthritis, chronic inflammatory bowel diseases, or tuberculosis. Serum amyloid A is a protein that is produced during inflammation and infections. Persistently elevated levels in chronic diseases can lead to AA amyloidosis.
  • ATTR amyloidosis: This is caused by misfolding of the protein transthyretin, which is normally responsible for transporting thyroid hormones and vitamin A. The acquired form mainly affects men over 65; it is probably due to natural aging processes. In the inherited form (a genetic change in the transthyretin gene), the misfolded protein is produced from birth, but the first symptoms usually only appear in adulthood.

Symptoms of amyloidosis

The first symptoms of amyloidosis are often hard to recognize, because the complaints are nonspecific and depend on the organs affected. At the beginning, general tiredness, a markedly reduced ability to cope with physical exertion, and exhaustion often occur. Organs that are frequently affected are the heart, the kidneys, the gastrointestinal tract, and the nervous system.

  • Heart: shortness of breath on exertion, fluid retention, fast pulse
  • Kidneys: fluid retention, foamy urine (due to loss of protein through the kidneys)
  • Gastrointestinal tract: loss of appetite, weight loss, diarrhea
  • Nervous system: altered sensation in the hands and feet, carpal tunnel syndrome on both sides (compression of a nerve in the hand that leads to numbness, tingling, or pain)

These symptoms are general and can also occur in many other diseases. If the complaints are new, get worse, or persist for a longer time, you should see a doctor.

When is AL amyloidosis treated?

The following sections mainly deal with the treatment of . AL amyloidosis is treated as soon as organs are affected, i.e. when there are symptoms or signs of impaired organ function in blood or urine tests.

How is AL amyloidosis treated?

As a rule, the aim is causal treatment, which means treating the cause. The goal is to stop the production of the amyloid-forming light chains by killing the diseased plasma cells that produce the light chains. Treatment is currently based on the risk profile, which mainly takes into account heart function and thus the patient's suitability for certain therapies.

  • High-dose therapy with stem cell transplantation: High-dose chemotherapy followed by a transplant of the patient's own stem cells, in which blood stem cells collected beforehand are returned after the high-dose treatment to restore blood formation. Only suitable for patients who meet certain criteria.
  • Chemoimmunotherapy: A combination of the antibody daratumumab and chemotherapy (bortezomib, cyclophosphamide, and dexamethasone); today the standard treatment for most newly diagnosed patients.

How exactly have clinical trials changed the treatment landscape for AL amyloidosis?

In 2022, the International Society of Amyloidosis (ISA) and the European Hematology Association (EHA) published a guideline on the treatment of AL amyloidosis with high-dose therapy and stem cell transplantation as well as a guideline on the treatment of patients who are not suitable for high-dose therapy.

High-dose therapy with stem cell transplantation

  • In a with 100 patients, high-dose therapy with stem cell transplantation did not show an advantage over the standard chemotherapy of the time (melphalan and dexamethasone). However, patients with severe heart disease were also included, which led to a high treatment-related mortality and probably influenced the result. (DOI: 10.1056/NEJMoa070484)
  • In contrast, other long-term observational studies showed that selected patients can survive for a very long time after high-dose therapy with stem cell transplantation. (DOI: 10.1182/blood-2011-01-330738)
  • What matters, therefore, is the selection of suitable patients and treatment in transplant centers that specialize in amyloidosis. Through these measures, treatment-related mortality has been reduced to below 5 %. (DOI: 10.1182/blood-2011-01-330738)

Chemoimmunotherapy

  • The ANDROMEDA trial investigated, in 388 patients, a combination of the antibody daratumumab and chemotherapy compared with the standard chemotherapy of the time alone. The results showed a marked improvement in hematologic response, meaning that the abnormal light chains in the blood disappeared completely more often with the combination. As a result of this trial, patients with newly diagnosed AL amyloidosis have been treated with this chemoimmunotherapy since 2021. (DOI: 10.1056/NEJMoa2028631)

This information is not a substitute for a conversation with your doctor.